Clinical value of neutrophil-to-lymphocyte ratio as a predictor of prognosis of RetroNectin®-activated cytokine-induced killer cell therapy in advanced non-small-cell lung cancer

Immunotherapy. 2019 Mar;11(4):273-282. doi: 10.2217/imt-2018-0147. Epub 2018 Dec 14.

Abstract

Aim: To assess the impact of neutrophil-to-lymphocyte ratio (NLR) on time to progression (TTP) and overall survival (OS) and explore the value of NLR as an indicator in patients with non-small-cell lung cancer (NSCLC) treated with RetroNectin®-activated cytokine-induced killer (R-CIK) cells.

Patients & methods: Using data gathered from a single center between January 2010 and June 2015, 201 patients with stage IIIB or IV NSCLC receiving at least four cycles of R-CIK cell therapy were included. Univariate and multivariate Cox regression analyses were performed to evaluate the associations of NLR with TTP and OS.

Results: The pretreatment NLR was correlated with TTP and OS. Multivariate analysis showed that NLR was an independent factor for survival.

Conclusion: NLR was an independent indicator to predict benefit from R-CIK-based combination therapy.

Keywords: RetroNectin; advanced; cytokine-induced killer cells; lung cancer; neutrophil-to-lymphocyte ratio; non-small cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Cells, Cultured
  • Cytokine-Induced Killer Cells / immunology*
  • Female
  • Fibronectins / metabolism
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / therapy
  • Lymphocytes / immunology*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neutrophils / immunology*
  • Predictive Value of Tests
  • Prognosis
  • Recombinant Proteins / metabolism

Substances

  • Fibronectins
  • Recombinant Proteins
  • retronectin